In consideration of the low number of TP53 mutated B-CLL patient samples examined, further studies on a larger cohort are necessary to ascertain whether Nutlin-3, or other non-genotoxic activator of the p53 pathway, might exhibit therapeutic benefits in a subset of TP53 mutated BCLL patients. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.